Prostate cancer gene therapy clinical trials (Q36779377)

16 August 2017

1 reference

title

Prostate cancer gene therapy clinical trials (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

Svend O Freytag

1

1 reference

16 August 2017

Hans Stricker

series ordinal

2

1 reference

16 August 2017

Benjamin Movsas

series ordinal

3

1 reference

16 August 2017

Jae Ho Kim

series ordinal

4

1 reference

16 August 2017

3 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

15

1 reference

16 August 2017

6

1 reference

16 August 2017

1042-1052

1 reference

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Predictors of mortality after prostate-specific antigen failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

The clinical significance of a positive post-irradiation prostatic biopsy without metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300162

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300162

1 reference

16 August 2017

1 reference